714 related articles for article (PubMed ID: 30586620)
41. A comprehensive analysis of coagulopathy during anti-B cell maturation antigen chimeric antigen receptor-T therapy in multiple myeloma, a retrospective study based on LEGEND-2.
Liu R; Lv Y; Hong F; Zhao W; Lei B; Liu J; Zhang W; He A; Wang F
Hematol Oncol; 2023 Oct; 41(4):704-717. PubMed ID: 37186314
[TBL] [Abstract][Full Text] [Related]
42. IL-6: from arthritis to CAR-T-cell therapy and COVID-19.
Kishimoto T
Int Immunol; 2021 Sep; 33(10):515-519. PubMed ID: 33715009
[TBL] [Abstract][Full Text] [Related]
43. Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy.
Riegler LL; Jones GP; Lee DW
Ther Clin Risk Manag; 2019; 15():323-335. PubMed ID: 30880998
[TBL] [Abstract][Full Text] [Related]
44. Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial.
Schuster SJ; Maziarz RT; Rusch ES; Li J; Signorovitch JE; Romanov VV; Locke FL; Maloney DG
Blood Adv; 2020 Apr; 4(7):1432-1439. PubMed ID: 32271899
[TBL] [Abstract][Full Text] [Related]
45. Severe dyspnea caused by rapid enlargement of cervical lymph node in a relapsed/refractory B-cell lymphoma patient following chimeric antigen receptor T-cell therapy.
Jin A; Feng J; Wang Z; Jiang L; Hu Y; Zhao K; Huang H
Bone Marrow Transplant; 2019 Jul; 54(7):969-972. PubMed ID: 30563981
[TBL] [Abstract][Full Text] [Related]
46. Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS).
Wehrli M; Gallagher K; Chen YB; Leick MB; McAfee SL; El-Jawahri AR; DeFilipp Z; Horick N; O'Donnell P; Spitzer T; Dey B; Cook D; Trailor M; Lindell K; Maus MV; Frigault MJ
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34996813
[TBL] [Abstract][Full Text] [Related]
47. IL-6/IFN-γ double knockdown CAR-T cells reduce the release of multiple cytokines from PBMCs in vitro.
Zhang H; Lv X; Kong Q; Tan Y
Hum Vaccin Immunother; 2022 Dec; 18(1):1-14. PubMed ID: 35049413
[TBL] [Abstract][Full Text] [Related]
48. Building safety into CAR-T therapy.
Peters DT; Savoldo B; Grover NS
Hum Vaccin Immunother; 2023 Dec; 19(3):2275457. PubMed ID: 37968136
[TBL] [Abstract][Full Text] [Related]
49. Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.
Teachey DT; Lacey SF; Shaw PA; Melenhorst JJ; Maude SL; Frey N; Pequignot E; Gonzalez VE; Chen F; Finklestein J; Barrett DM; Weiss SL; Fitzgerald JC; Berg RA; Aplenc R; Callahan C; Rheingold SR; Zheng Z; Rose-John S; White JC; Nazimuddin F; Wertheim G; Levine BL; June CH; Porter DL; Grupp SA
Cancer Discov; 2016 Jun; 6(6):664-79. PubMed ID: 27076371
[TBL] [Abstract][Full Text] [Related]
50. Chimeric Antigen Receptor T-cell Therapy for Multiple Myeloma.
Atrash S; Ali SA; Usmani SZ
Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):21-34. PubMed ID: 33046423
[TBL] [Abstract][Full Text] [Related]
51. Extracorporeal cytokine removal in severe CAR-T cell associated cytokine release syndrome.
Stahl K; Schmidt BMW; Hoeper MM; Skripuletz T; Möhn N; Beutel G; Eder M; Welte T; Ganser A; Falk CS; Koenecke C; David S
J Crit Care; 2020 Jun; 57():124-129. PubMed ID: 32113143
[TBL] [Abstract][Full Text] [Related]
52. Management of Chimeric Antigen Receptor (CAR) T-Cell Toxicities: A Review and Guideline for Emergency Providers.
Gupta R; Roach C; Hryniewicki AT; Vilke GM; Shatsky RA; Coyne CJ
J Emerg Med; 2020 Jul; 59(1):61-74. PubMed ID: 32473867
[TBL] [Abstract][Full Text] [Related]
53. Management and Prevention of Cellular-Therapy-Related Toxicity: Early and Late Complications.
Mucha SR; Rajendram P
Curr Oncol; 2023 May; 30(5):5003-5023. PubMed ID: 37232836
[TBL] [Abstract][Full Text] [Related]
54. Suppression of cytokine release syndrome during CAR-T-cell therapy via a subcutaneously injected interleukin-6-adsorbing hydrogel.
Li X; Gong N; Tian F; Zhang S; Zhang Y; Wang Y; Qing G; Wang Y; Li F; Xu Y; Zhang L; Wang J; Ni Q; Gan Y; Gu C; Jiang H; Huang X; Shi X; Zhang T; Wu Y; Liang XJ
Nat Biomed Eng; 2023 Sep; 7(9):1129-1141. PubMed ID: 37696984
[TBL] [Abstract][Full Text] [Related]
55. Toxicities of chimeric antigen receptor T cells: recognition and management.
Brudno JN; Kochenderfer JN
Blood; 2016 Jun; 127(26):3321-30. PubMed ID: 27207799
[TBL] [Abstract][Full Text] [Related]
56. Chimeric Antigen Receptor T Cells in Hematologic Malignancies.
Shank BR; Do B; Sevin A; Chen SE; Neelapu SS; Horowitz SB
Pharmacotherapy; 2017 Mar; 37(3):334-345. PubMed ID: 28079265
[TBL] [Abstract][Full Text] [Related]
57. Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies: A Practical Review.
Strati P; Gregory T; Majhail NS; Jain N
JCO Oncol Pract; 2023 Sep; 19(9):706-713. PubMed ID: 37406255
[TBL] [Abstract][Full Text] [Related]
58. Emerging approaches for preventing cytokine release syndrome in CAR-T cell therapy.
Balagopal S; Sasaki K; Kaur P; Nikolaidi M; Ishihara J
J Mater Chem B; 2022 Sep; 10(37):7491-7511. PubMed ID: 35912720
[TBL] [Abstract][Full Text] [Related]
59. The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities.
Gutierrez C; Brown ART; Herr MM; Kadri SS; Hill B; Rajendram P; Duggal A; Turtle CJ; Patel K; Lin Y; May HP; Gallo de Moraes A; Maus MV; Frigault MJ; Brudno JN; Athale J; Shah NN; Kochenderfer JN; Dharshan A; Beitinjaneh A; Arias AS; McEvoy C; Mead E; Stephens RS; Nates JL; Neelapu SS; Pastores SM
J Crit Care; 2020 Aug; 58():58-64. PubMed ID: 32361219
[TBL] [Abstract][Full Text] [Related]
60. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies.
Freyer CW; Porter DL
J Allergy Clin Immunol; 2020 Nov; 146(5):940-948. PubMed ID: 32771558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
